VectivBio

Biotech company develops treatments for severe rare diseases, aims to become global leader with patient-centric approach.

General Information
Company Name
VectivBio
Founded Year
2019
Location (Offices)
Basel, Switzerland +1
Founders / Decision Makers
Number of Employees
57
Industries
Biotechnology, Health Care
Funding Stage
Post Ipo Equity
Social Media

VectivBio - Company Profile

VectivBio is a biotech company founded in 2019 based in Switzerland. The company's mission is to develop treatments for severe rare diseases and aims to become a global leader with a patient-centric approach. They have received a significant $125.00M investment in post-IPO equity funding from a consortium of investors including Forbion, OrbiMed, Vivo Capital, Marshall Wace, Driehaus Capital Management, TCG Crossover, Venrock Healthcare Capital Partners, Eventide Asset Management, Surveyor Capital, and Frazier Life Sciences on 13 October 2022. The company is dedicated to discovering and developing novel therapies for severe rare ailments with significant unaddressed medical needs. Their goal is to establish a preeminent, wholly integrated global enterprise specializing in severe rare illnesses through a patient-oriented strategy. VectivBio possesses a top-quality squad with extensive proficiency in severe rare ailments and a history of accomplishing research and development, product commercialization, and business expansion for innovative therapies directed towards orphan conditions with significant medical needs. With their strong investor backing and focused approach, VectivBio is poised to make significant strides in addressing unmet medical needs in the biotechnology and healthcare industries.

Taxonomy: biotech, clinical-stage, rare diseases, global leader, patient-centric approach, novel therapies, unaddressed medical needs, integrated global enterprise, patient-oriented, life-changing drugs, product commercialization, business expansion, orphan conditions, medical needs

Funding Rounds & Investors of VectivBio (5)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $125.00M 10 Surveyor Capital 13 Oct 2022
Post-IPO Equity $54.00M - 29 Jun 2022
Post-IPO Debt $75.00M - 30 Mar 2022
Venture Round $110.00M - 19 Oct 2020
Series A $35.00M - 08 Jan 2020

Latest News of VectivBio

View All

No recent news or press coverage available for VectivBio.

Similar Companies to VectivBio

View All
Hong Kong Winhealth Pharma Group - Similar company to VectivBio
Hong Kong Winhealth Pharma Group Providing novel breakthrough therapies for patients with rare diseases and other unmet medical needs.
Oakrum Pharma, LLC - Similar company to VectivBio
Oakrum Pharma, LLC Because you matter
CureGRIN Foundation - Similar company to VectivBio
CureGRIN Foundation CureGRIN Foundation is a parent-run charity dedicated to improving the lives of people living with GRI disorders.
Reistone Biopharma - Similar company to VectivBio
Reistone Biopharma Focusing on rapidly developing innovative medicines through global collaborations within Research and Development